Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells - PubMed (original) (raw)
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
Estrella Mariel Levy et al. Innate Immun. 2009 Apr.
Free article
Abstract
Cetuximab, an anti-epidermal growth factor receptor monoclonal antibody, has been shown to increase the median survival of colorectal cancer patients. We previously reported that the expression of HLA-E is significantly increased in primary human colorectal cancer, perhaps contributing to tumour escape from immune surveillance. To establish if HLA-E could be a factor that renders colorectal cancer cells less susceptible to antibody-dependent cellular cytotoxicity (ADCC), in the present study we analysed Cetuximab-mediated cytotoxicity against several colorectal cancer cell lines expressing, or not, HLA-E at the cell surface. We first observed that colorectal cancer cells treated with Cetuximab were killed more efficiently by ADCC. Interestingly, treatment of target cells with recombinant human-beta2-microglobulin inhibits Cetuximab-mediated ADCC through HLA-E membrane stabilization. The specific immunosuppressive role of HLA-E was confirmed using an anti-NKG2A monoclonal antibody, that restored the ability of immune cells to kill their target. This result demonstrates that HLA-E at the cell surface can reliably suppress the ADCC effect. On the other hand, Cetuximab induced a direct growth inhibition but only at high concentrations; furthermore, the CDC effect was quite moderate, and we failed to observe a pro-apoptotic effect. Taking into account that our findings suggest that ADCC activity is the main anti-tumour effect observed at clinically achievable concentrations of Cetuximab at the tumour site, we suggest that determination of HLA-E in colorectal cancer could be relevant to predict success of Cetuximab treatment.
Similar articles
- Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.
Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, Valvassori L, Mordoh J. Levy EM, et al. Int J Oncol. 2008 Mar;32(3):633-41. Int J Oncol. 2008. PMID: 18292941 - Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E. Kurai J, et al. Clin Cancer Res. 2007 Mar 1;13(5):1552-61. doi: 10.1158/1078-0432.CCR-06-1726. Clin Cancer Res. 2007. PMID: 17332301 - B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B. Borgerding A, et al. Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6. Exp Hematol. 2010. PMID: 20056126 - Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF. Wong SF. Clin Ther. 2005 Jun;27(6):684-94. doi: 10.1016/j.clinthera.2005.06.003. Clin Ther. 2005. PMID: 16117976 Review. - Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
Figueiredo C, Blaszczyk R. Figueiredo C, et al. J Stem Cells. 2014;9(3):149-61. J Stem Cells. 2014. PMID: 25157449 Review.
Cited by
- Cell Surface B2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA?
Ravindranath MH, Ravindranath NM, Selvan SR, Hilali FE, Amato-Menker CJ, Filippone EJ. Ravindranath MH, et al. Biomolecules. 2023 Jul 28;13(8):1178. doi: 10.3390/biom13081178. Biomolecules. 2023. PMID: 37627243 Free PMC article. Review. - Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J, Keam B, Park HR, Park JE, Kim S, Kim M, Kim TM, Kim DW, Heo DS. Lee J, et al. J Cancer Res Clin Oncol. 2023 Aug;149(9):5705-5715. doi: 10.1007/s00432-022-04532-x. Epub 2022 Dec 22. J Cancer Res Clin Oncol. 2023. PMID: 36547689 - Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines.
Ravindranath MH, Ravindranath NM, Selvan SR, Filippone EJ, Amato-Menker CJ, El Hilali F. Ravindranath MH, et al. Vaccines (Basel). 2022 Feb 21;10(2):339. doi: 10.3390/vaccines10020339. Vaccines (Basel). 2022. PMID: 35214796 Free PMC article. Review. - The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.
Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken JB, Lardon F, De Waele J, Wouters A. Baysal H, et al. Front Immunol. 2021 Sep 7;12:737311. doi: 10.3389/fimmu.2021.737311. eCollection 2021. Front Immunol. 2021. PMID: 34557197 Free PMC article. Review. - High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis.
Denis Musquer M, Jouand N, Pere M, Lamer JE, Bézieau S, Matysiak T, Faroux R, Caroli Bosc FX, Rousselet MC, Leclair F, Mosnier JF, Toquet C, Gervois N, Bossard C. Denis Musquer M, et al. Front Oncol. 2021 Jun 15;11:684478. doi: 10.3389/fonc.2021.684478. eCollection 2021. Front Oncol. 2021. PMID: 34211852 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials